Revolution Medicines Files Q1 2025 10-Q
Ticker: RVMDW · Form: 10-Q · Filed: May 7, 2025 · CIK: 1628171
| Field | Detail |
|---|---|
| Company | Revolution Medicines, Inc. (RVMDW) |
| Form Type | 10-Q |
| Filed Date | May 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financial-reporting, biotech
TL;DR
RVMD Q1 2025 10-Q filed. Financials updated, fair value measurements detailed.
AI Summary
Revolution Medicines, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 700 Saginaw Drive, Redwood City, CA, reported on its financial status. Key financial reporting elements include fair value measurements for various investments and liabilities, with specific mentions of Level 1, Level 2, and Level 3 inputs.
Why It Matters
This filing provides investors with an update on Revolution Medicines' financial health and operational details for the first quarter of 2025, crucial for understanding the company's performance and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Revolution Medicines faces inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial reporting.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
- 2024-12-31 — Previous Year End Date (Provides a comparative point for financial analysis.)
- 2023-12-31 — Prior Year End Date (Offers further historical context for financial trends.)
Key Players & Entities
- Revolution Medicines, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — Period of report
- 700 Saginaw Drive, Redwood City, CA (location) — Company business and mailing address
- Jeff Cislini (person) — Mentioned in relation to financial reporting
FAQ
What are the primary financial instruments for which fair value measurements are reported?
The filing details fair value measurements for instruments including Commercial Paper, Money Market Funds, Certificates of Deposit, Corporate Debt Securities, and Warrant Liability.
What is the significance of 'FairValueInputsLevel1Member', 'Level2Member', and 'Level3Member' in this filing?
These terms refer to the hierarchy of inputs used in fair value measurements, with Level 1 being quoted prices in active markets, Level 2 being observable inputs other than quoted prices, and Level 3 being unobservable inputs.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
What is the SEC file number for Revolution Medicines, Inc.?
The SEC file number is 001-39219.
What type of business is Revolution Medicines, Inc. primarily involved in?
Revolution Medicines, Inc. is primarily involved in Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 7, 2025 by Jeff Cislini regarding Revolution Medicines, Inc. (RVMDW).